

SCIENTIFIC PANEL ON NUTRITION, NOVEL FOODS AND FOOD ALLERGENS

MINUTES OF THE 113TH PLENARY MEETING

**Held on 27-29 April 2021 via web conference
(Agreed on 06 May 2021)**

Participants

■ Panel Members:

Jacqueline Castenmiller, Stefaan de Henauw, Karen Ildico Hirsch-Ernst¹, John Kearney, Helle Katrine Knutsen, Alexandre Maciuk, Inge Mangelsdorf, Harry J. McArdle, Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsabouri, Dominique Turck (Chair) and Marco Vinceti.

■ Hearing Experts:

Not Applicable

■ European Commission:

Stella D'Amore, Ivona Babic, Stefanie Bodenbach, Takis Daskaleros, Panagiota Filippou, Olga Goulaki and Rafael Perez-Berbejal,

■ EFSA:

NUTRI Unit: Valeriu Curtui, Janusz Ciok, Ionut Craciun, Wolfgang Gelbmann, Leng Heng, Leonard Matijevic, Agnès de Sesmaisons, Céline Dumas, Ruth Roldán Torres, Ariane Titz and Silvia Valtueña Martínez.

AMU Unit: Laura Ciccolallo, Valeria Ercolano, Laura Martino (item 8.3)

■ Others:

Anna Karin Lindroos (as an observer for item 8.3)

¹ Did not attend on the last day



1. Welcome and apologies for absence

The Chair welcomed the participants. Apologies were not received.

2. Adoption of agenda

The agenda was adopted without changes.

3. Declarations of Interest of Scientific Panel members

In accordance with EFSA's Policy on Independence² and the Decision of the Executive Director on Competing Interest Management³, EFSA screened the Annual Declarations of Interest filled out by the Panel members invited to the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process, and no interests were declared orally by the members at the beginning of this meeting.

4. The minutes of the 112th Plenary meeting held on 08 April 2021

The minutes of the 112th Plenary meeting held on 08 April 2021 were agreed by written procedure on 16 April 2021.

5. Scientific outputs submitted for discussion and/or possible adoption

5.1 Draft opinion on UV-treated baker's yeast (*Saccharomyces cerevisiae*) as a novel food (NF 2020/1778) Applicant: *Lallemand Bio-Ingredients Division* (EFSA-Q-2020-00393)

The draft opinion on an extension of use was presented. The Panel reviewed and discussed proposed uses and use levels and anticipated daily intakes of the Novel Food. The opinion was adopted by the Panel on 28 April subject to the incorporation of editorial changes. The full text of the opinion will be available in the coming weeks in the EFSA Journal via the following link: <http://www.efsa.europa.eu/en/efsajournal/pub/6602>

5.2 Draft opinion on dried fruits of *Synsepalum dulcificum* as a novel food (NF 2018/0709). Applicant: *Baïa Food Co. (Medicinal Gardens S.L.)* (EFSA-Q-2018-01032)

The draft opinion was presented. The Panel reviewed and discussed the sections regarding production process, compositional data, specifications, toxicology and allergenicity of the Novel Food. The opinion was adopted by the Panel on 27 April subject to the incorporation of editorial changes. The full text of the opinion will be available in the coming weeks in the EFSA Journal via the following link: <http://www.efsa.europa.eu/en/efsajournal/pub/6600>.

5.3 Draft opinion on the efficacy of an infant formula manufactured from a specific protein hydrolysate derived from whey protein isolate and concentrate in reducing the risk of developing atopic dermatitis. Applicant: *Société des Produits Nestlé S.A.* (EFSA-Q-2019-00529)

The draft opinion was presented. The Panel reviewed and discussed the sections regarding the characterisation of the protein hydrolysate, the characterisation of the formula

² http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/policy_independence.pdf

³ http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/competing_interest_management_17.pdf



manufactured from this hydrolysate and used in the clinical studies provided, and the human intervention studies submitted to support the nutritional safety and suitability of the protein hydrolysate. The opinion was adopted by the Panel on 29 April subject to the incorporation of editorial changes. The full text of the opinion will be available in the coming weeks in the EFSA Journal via the following link: <http://www.efsa.europa.eu/en/efsajournal/pub/6603>

5.4 Draft opinion on Green kiwifruit (lat. *Actinidia deliciosa* var. Hayward) and maintenance of normal defecation. Applicant: Zespri International Limited (0498_BE - Art. 13.5 Claim, Reg.(EC) No 1924/2006, EFSA-Q-2020-00562)

The draft opinion was presented. The Panel reviewed and discussed the sections regarding the characterisation of the food/constituent, relevance of the claimed effect to human health, and the scientific substantiation of the claimed effect taking into consideration the data submitted in the present application including the applicant's replies to EFSA's stop-the-clock letters. A revised draft opinion incorporating changes will be re-submitted to the NDA Panel⁴ for discussion/possible adoption.

6. New mandates

Postponed.

7. Feedback from the Scientific Committee/Scientific Panels, EFSA, the European Commission

Postponed.

8. Other scientific topics for information and/or discussion

8.1 Draft opinion on Nicotinamide Riboside chloride as a novel food (NF 2020/1613) Applicant: ChromaDex, Inc. Scientific (EFSA-Q-2020-00289)

The Panel was given an overview on the status of the application. The Panel discussed and took note of the approach for the risk assessment.

8.2 Draft opinion on Calcdiol as a novel food (NF 2018/0402) Applicant: DSM Nutritional Products Ltd. (EFSA-Q-2018-00514)

The Panel was given an overview on the status of the application. The Panel discussed and took note of the approach for the risk assessment.

8.3 Draft opinion on the Tolerable Upper Intake Level of dietary sugars (EFSA-Q-2020-00414)

The Panel was given a complete overview of the draft opinion before opening it for comments before the next Plenary meeting, up to the section on hazard identification. The Panel was consulted on specific aspects of the scientific assessment to gather feedback, which will be shared with the WG on sugars.

⁴ At the NDA Plenary meeting to be held on 7 May 2021.



9. Any Other Business

- The next plenary meeting of the NDA Panel is scheduled on 7 May 2021 via web conference.